drugset
drugset / Trial / NCT04833049

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049 ↗

Phase 1 Completed 6 enrolled Takeda
NaSequentialOpen-labelOther

Summary

The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.

Timeline

Start
2021-04-14
Primary completion
2021-06-20
Completion
2021-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-994 Unknown — Oral

Indications

No indication recorded.